ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.250,87
0,49%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06879
-0,20%
Bitcoin
61.236,42
-0,93%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) News

ARGX

argenx (ARGX)

argenx SE
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARGX
DatumZeitQuelleÜberschriftSymbolFirma
25/06/202422h30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingNASDAQ:ARGXargenx SE
21/06/202422h50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
17/06/202412h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
17/06/202407h00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024NASDAQ:ARGXargenx SE
04/06/202407h00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
09/05/202413h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
09/05/202407h00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
08/05/202412h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
07/05/202423h30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
07/05/202407h00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
02/05/202407h00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
16/04/202407h00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseNASDAQ:ARGXargenx SE
27/03/202407h00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseNASDAQ:ARGXargenx SE
26/03/202421h00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024NASDAQ:ARGXargenx SE
26/03/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
08/03/202412h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
07/03/202422h01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingNASDAQ:ARGXargenx SE
29/02/202422h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
29/02/202407h00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
26/02/202407h00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
22/02/202407h00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024NASDAQ:ARGXargenx SE
20/02/202412h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
20/02/202407h00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
18/01/202412h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
18/01/202407h00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
08/01/202412h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
08/01/202407h00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesNASDAQ:ARGXargenx SE
02/01/202407h00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
20/12/202318h37Dow Jones NewsArgenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data TalkNASDAQ:ARGXargenx SE
20/12/202312h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Kürzlich von Ihnen besucht

BIT
P1Q5U0
BNP Paribas Issuance
BOV
PETRV34
PETRV34 Ex:28,89
BIT
UC4YAP
Unicredit Bank
BOV
BDAP11
ETF
USOTC
AUSI
Aura Systems (PK)
NASDAQ
TXUI
Texas United Bancshares
BIT
P1Z588
NLBNPIT1Z588 20991231 26...
ASX
LCL
LCL Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten